ovarian cancer

[Journal of Clinical Investigation] Investigators used an accurate, single-cell whole genome sequencing approach to first show that telomerized primary mammary epithelial cells heterozygous for a highly penetrant BRCA1 variant displayed a robustly elevated mutation frequency as compared to their isogenic control cells.

[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the US FDA has cleared the company’s Investigational New Drug application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor NK cell product candidate.

[BioAtla, Inc. (PR Newswire, Inc.)] BioAtla, Inc. announced that it has entered into a clinical collaboration with Bristol Myers Squibb to investigate BioAtla's two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb's anti-PD-1 therapy nivolumab.

[Cell Reports] Researchers generated human fallopian tube epithelial (FTE) organoids from BRCA1 mutation carriers that provided a faithful physiological in vitro model of FTE lesion generation and early carcinogenesis.

[SOTIO Biotech] SOTIO Biotech announced that it has entered into a clinical trial collaboration and supply agreement with MSD to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® in patients with selected advanced/refractory solid tumors in the Phase II AURELIO-04 study.

[Cancer Immunology Research] An epigenetic CRISPR-Cas9 screen of 1,218 chromatin regulators identified TRIM28 as a suppressor of PD-L1 expression.